PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components

Poly(ADP-ribose) polymerase inhibitors (PARPi) have been in clinical use since 2014 for certain patients with germline BRCA1/2 mutations, but as evidence and approvals for their use in a wider range of patients grow, the question of how best to identify patients who would benefit from PARPi becomes...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Sullivan Coyne, Geraldine, Karlovich, Chris, Wilsker, Deborah, Voth, Andrea Regier, Parchment, Ralph E, Chen, Alice P, Doroshow, James H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885121/
https://www.ncbi.nlm.nih.gov/pubmed/35237050
http://dx.doi.org/10.2147/OTT.S278092
_version_ 1784660333507379200
author O’Sullivan Coyne, Geraldine
Karlovich, Chris
Wilsker, Deborah
Voth, Andrea Regier
Parchment, Ralph E
Chen, Alice P
Doroshow, James H
author_facet O’Sullivan Coyne, Geraldine
Karlovich, Chris
Wilsker, Deborah
Voth, Andrea Regier
Parchment, Ralph E
Chen, Alice P
Doroshow, James H
author_sort O’Sullivan Coyne, Geraldine
collection PubMed
description Poly(ADP-ribose) polymerase inhibitors (PARPi) have been in clinical use since 2014 for certain patients with germline BRCA1/2 mutations, but as evidence and approvals for their use in a wider range of patients grow, the question of how best to identify patients who would benefit from PARPi becomes ever more complex. Here, we discuss the development and current state of approved selection testing for PARPi therapy and the ongoing efforts to define a broader range of homologous recombination repair deficiencies that are susceptible to PARP inhibition.
format Online
Article
Text
id pubmed-8885121
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-88851212022-03-01 PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components O’Sullivan Coyne, Geraldine Karlovich, Chris Wilsker, Deborah Voth, Andrea Regier Parchment, Ralph E Chen, Alice P Doroshow, James H Onco Targets Ther Review Poly(ADP-ribose) polymerase inhibitors (PARPi) have been in clinical use since 2014 for certain patients with germline BRCA1/2 mutations, but as evidence and approvals for their use in a wider range of patients grow, the question of how best to identify patients who would benefit from PARPi becomes ever more complex. Here, we discuss the development and current state of approved selection testing for PARPi therapy and the ongoing efforts to define a broader range of homologous recombination repair deficiencies that are susceptible to PARP inhibition. Dove 2022-02-24 /pmc/articles/PMC8885121/ /pubmed/35237050 http://dx.doi.org/10.2147/OTT.S278092 Text en © 2022 O’Sullivan Coyne et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
O’Sullivan Coyne, Geraldine
Karlovich, Chris
Wilsker, Deborah
Voth, Andrea Regier
Parchment, Ralph E
Chen, Alice P
Doroshow, James H
PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
title PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
title_full PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
title_fullStr PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
title_full_unstemmed PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
title_short PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
title_sort parp inhibitor applicability: detailed assays for homologous recombination repair pathway components
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885121/
https://www.ncbi.nlm.nih.gov/pubmed/35237050
http://dx.doi.org/10.2147/OTT.S278092
work_keys_str_mv AT osullivancoynegeraldine parpinhibitorapplicabilitydetailedassaysforhomologousrecombinationrepairpathwaycomponents
AT karlovichchris parpinhibitorapplicabilitydetailedassaysforhomologousrecombinationrepairpathwaycomponents
AT wilskerdeborah parpinhibitorapplicabilitydetailedassaysforhomologousrecombinationrepairpathwaycomponents
AT vothandrearegier parpinhibitorapplicabilitydetailedassaysforhomologousrecombinationrepairpathwaycomponents
AT parchmentralphe parpinhibitorapplicabilitydetailedassaysforhomologousrecombinationrepairpathwaycomponents
AT chenalicep parpinhibitorapplicabilitydetailedassaysforhomologousrecombinationrepairpathwaycomponents
AT doroshowjamesh parpinhibitorapplicabilitydetailedassaysforhomologousrecombinationrepairpathwaycomponents

Ejemplares similares